{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-038385","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2026-08-14T20:15:54+00:00","discovered_at":"2026-08-14T20:24:00.845452+00:00","generated_at":"2026-08-14T20:24:27.743397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enveric Biosciences Q2 2026 net loss $3.0M, cash $8.3M, EB-003 IND studies advance","bullets":["Net loss $3.0M ($0.76/share) vs $2.5M ($11.65/share) in Q2 2025; cash $8.3M at June 30, 2026.","Raised $5.0M gross from private placement plus $1.5M from warrant exercises during Q2.","Advanced EB-003 IND-enabling studies: genotoxicity initiated, non-hallucinogenic GloSensor data, no photoreactivity.","Secured U.S. Patent 12,605,361 for EVM301 series; received USPTO Notice of Allowance for EVM401 series.","Plans IND submission and Phase 1 trial for EB-003 in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-038385","json":"https://secwatch.observer/filing/0001493152-26-038385.json","markdown":"https://secwatch.observer/filing/0001493152-26-038385.md","text":"https://secwatch.observer/filing/0001493152-26-038385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/0001493152-26-038385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:24:27.743397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}